ライフサイエンスコーパス: i.m.

1 i.m. injection of AS01 enhances immune cell activation a

2 i.m. inoculation was inferior to i.n. inoculation at ind

3 i.m. inoculation with inactivated EDIM, cell culture-ada

4 i.m. inoculation with live, wild-type rotavirus (murine

5 i.m.-immunized pigs generated a high titer of neutralizi

6 e injected a plasmid DNA encoding TGF-beta 1 i.m. to the SCW animals to determine the effect of TGF-b

7 plasma triglycerides by 38% (i.p.) and 26% (i.m.) was obtained.

8 ty in skeletal muscle by 58% (i.p.) and 36% (i.m.) when compared with control-injected mice.

9 Although most vaccines are administered i.m., little is known about the dendritic cells (DCs) th

10 .m.; group B), or 7.2 mg of DNA administered i.m. (high-dose group C) each time.

11 Dexamethasone was administered i.m. to pregnant ewes as 3 weekly courses (4 x 2 mg at 1

12 mg/kg M100+0.3 mg/kg WAY) were administered i.m. before lights-out.

13 After i.m. administration of Ag adsorbed to alum, we showed th

14 After i.m. immunization, the microparticles induced significan

15 s I MHC presentation of viral antigens after i.m. immunization with plasmid DNA.

16 rbed DNA into antigen-presenting cells after i.m. injection.

17 Three days after i.m. immunization with rotavirus, cells obtained from th

18 heart, lung, liver, and spleen 7 days after i.m. injection of p21 sense plasmid DNA.

19 and the immunogenicity was determined after i.m. immunization in combination with in vivo electropor

20 e responses to AAV capsid that develop after i.m. injection of a serotype 1 rAAV vector expressing AA

21 he predominant site of gene expression after i.m. immunization of plasmid DNA, but it is not clear if

22 pable of contributing to muscle fibers after i.m. injection.

23 gut-associated lymphoid tissue (GALT) after i.m. immunization.

24 of response was significantly greater after i.m. jet injection.

25 at 1, 2, 4, 8, 24, 48, 120, and 168 h after i.m. injection of 30 micro g of IFN-beta-1a.

26 lum-induced adaptive cellular immunity after i.m. vaccination.

27 rsely, the highest transfection levels after i.m. administration were achieved with naked DNA, follow

28 mune response in the lymphatic network after i.m. and s.c. injection of a clinically relevant vaccine

29 s formed invasive soft tissue sarcomas after i.m. injection into nude or scid mice.

30 ent and highly localized to the tissue after i.m. injection; it caused an increase in the number of A

31 fter i.p. immunization, as compared to after i.m. immunization.

32 ine induced significant local toxicity after i.m. injection, whereas C32 demonstrated no toxicity.

33 CD86 cDNA along with DNA encoding HIV-1 Ags i.m. dramatically increased Ag-specific CTL responses.

34 (oral group), intramuscularly (i.m.) alone (i.m. group), orally followed by i.m. (oral/i.m. group),

35 An i.m. or an intradermal administration of HSV:gp120 at th

36 boosted with Ad5.RSV-F i.n. 28 days after an i.m. dose also had significant increases in neutralizing

37 After an i.m. modified vaccinia Ankara/Gag boost, we observed rob

38 ing in the lymphatic vessels that connect an i.m. injection site with the local lymph node has not be

39 prime/gp120 boost to allow comparison of an i.m. immunization regimen to a mucosal vaccination regim

40 -PsVs expressing SIV genes, combined with an i.m. gp120 protein injection, induced humoral and cellul

41 rved that vaccination of BALB/c mice with an i.m. HBsAg-DNA vaccine prime followed by an intranasal b

42 d out in an athymic nude mouse model with an i.m. xenograft of LNCaP cells.

43 and i.m. routes prompted high levels of HI antibody titers a

44 and i.m. routes to induce serum antibody responses similar t

45 me-boost vaccination via sequential s.c. and i.m. administration yielded greater efficacy than any ot

46 ccination combining ivag HPV-gBsec/gDsec and i.m. gD2t-alum-MPL improved survival and reduced genital

47 33R, and B5R proteins by the intradermal and i.m. routes, either alone or in combination with the equ

48 xicity and DNA delivery after intratumor and i.m. injection.

49 ntramuscular (i.m.) immunization of mice and i.m. immunization of rabbits with formalinized staphyloc

50 e B HIV-1 gp160 by the intranasal (i.n.) and i.m. routes to compare mucosal and systemic routes of va

51 Repeated intraperitoneal (i.p.) and i.m. DNA administration increased the LPL activity in sk

52 DNA, intramuscularly (i.m.) in one study and i.m. and subcutaneously in another study.

53 icroneedle-based device is as efficacious as i.m. vaccination.

54 e immunized through different routes such as i.m., intradermally, or intratracheally with a DNA vacci

55 resting period, these macaques were boosted i.m. with the live-attenuated trachoma vaccine and their

56 In addition, both i.m. and i.n. plasmid immunizations failed to generate a

57 ice (Biojector) to deliver 1800 micro g both i.m. and intradermally (i.d.); 9 of 12 patients had humo

58 g mouse endostatin plus angiostatin (E+A) by i.m. injection.

59 by intradermal injection of pAra h2, and by i.m. injection of pOMC, the plasmid DNA encoding the maj

60 IFN-omega pDNA delivered by i.m. injection also had an antitumor effect.

61 ged into serotype 1 AAV capsids delivered by i.m. injection.

62 g properties distinct from those elicited by i.m. or i.n. rAd immunization.

63 i.m.) alone (i.m. group), orally followed by i.m. (oral/i.m. group), or i.m. followed by orally (i.m.

64 evels of interleukin-2 than those induced by i.m. immunization.

65 ignificantly different than those induced by i.m. immunization.

66 Ab response to beta-galactosidase induced by i.m. or intradermal injection of placZ, a plasmid DNA ve

67 tibody responses similar to those induced by i.m. prime/boost vaccination.

68 However, when infection was initiated by i.m., i.v., or i.p. routes, only a subset of the members

69 s from deer mice (Peromyscus maniculatus) by i.m. inoculation of 4- to 6-wk-old deer mouse pups.

70 to the antigen than immunization of mice by i.m. injection with the same plasmid did.

71 DNA immunization efficacy was optimized by i.m. delivery via electroporation, yet it remained modes

72 se coinjection reduces CD4 T-cell priming by i.m. injected antigen + alum.

73 static tumors can be treated systemically by i.m. injection of a plasmid encoding a cytokine gene.

74 contrast, using the i.m.-subcutaneous (s.c.)-i.m. regimen, it was found that gp120 and CTLA4:gp120 DN

75 MVAgp120 prime/combined i.m. (gp120) and i.n.

76 In comparison, i.m. injection of alphaS fibrils was more efficient in i

77 ewes received dexamethasone (2 x 12 mg daily i.m. injections in saline).

78 Direct i.m. injection of IL-12 cDNA induced activation of resti

79 Mice were injected with the naked DNA i.m., and immune responses were compared to those elicit

80 red to 263/331 (79%) receiving the five-dose i.m. regimen, showing non-inferiority of the simplified

81 col population was 1,002 children (five-dose i.m.: n = 331; three-dose i.m.: n = 338; three-dose i.v.

82 We compared both a three-dose i.m. and a three-dose i.v. parenteral ARS regimen with t

83 In the three-dose i.m. arm, 265/338 (78%) children had a >/= 99% reduction

84 A simplified three-dose i.m. regimen for severe malaria in African children is n

85 hildren (five-dose i.m.: n = 331; three-dose i.m.: n = 338; three-dose i.v.: n = 333); 139 participan

86 nderstanding of the role of adjuvants during i.m. vaccination needs to take into account the heteroge

87 DNA vaccines are usually administered either i.m. or intradermally.

88 tions of 4 mg/kg (at 0, 24, and 48 h) either i.m. (n = 348) or i.v. (n = 351), both of which were the

89 In this study, we evaluated i.m., aerosol (Aer), and simultaneous systemic and respi

90 s were also seen between CRs given Ad5.RSV-F i.m. and CRs given Ad5.RSV-F i.n.

91 Consistent with these findings, i.m. injection of the gp120/GM-CSF bicistronic DNA vacci

92 g/kg ARS as either a control regimen of five i.m. injections of 2.4 mg/kg (at 0, 12, 24, 48, and 72 h

93 s and antigen-specific CD4 T cells following i.m. injection.

94 systemic and mucosal compartments following i.m. immunization in 12 low- and high-risk HIV-1 seroneg

95 This effect is less dramatic following i.m. infection and is minimal after s.c. or intradermal

96 f the stability of gene expression following i.m. injection of RDAd.

97 y of CTL precursors (CTLp) in mice following i.m. injection with NP DNA or intranasal infection with

98 odies elicited to the SERA protein following i.m. and Gene Gun immunizations with SERA plasmid DNA wa

99 did not mount Ab or CTL responses following i.m. immunization with eukaryotic expression plasmids en

100 th CD8(+) T cell and Th1 responses following i.m. vaccination with Ag and nanoparticles, whereas the

101 ependencies on the injection site tissue for i.m. needle and epidermal gene gun DNA immunizations.

102 Furthermore, i.m. injection of soluble, nonaggregated alphaS in M83(+

103 Furthermore, i.m. or intradermal coinjection of pCD40L with placZ enh

104 Proteosome-toxoid plus alum given i.m. also elicited more significant protection against r

105 seen in CRs vaccinated with Ad5.RSV-F given i.m. or i.n., and these responses correlated with reduce

106 In contrast, resistant B10.D2 mice given i.m. injections with a recombinant adenovirus-expressing

107 8.2-fold greater than the same vaccine given i.m.), a response that could not be matched by antigen m

108 The high i.m. dose induced the responses of the greatest magnitud

109 Mice immunized i.m. with pB5 generated an antibody response that reduce

110 Negative-control groups were immunized i.m. and s.c. with Neisseria gonorrhoeae recombinant por

111 cally susceptible BALB/c mice were immunized i.m. with DNA for one or two Mycoplasma pulmonis Ags (A7

112 BALB/c mice were immunized i.m. with plasmid DNA encoding a model Ag HIV-1 Env gp14

113 ring 7.6-8-mm MCa-4 mammary tumors implanted i.m. into the right posterior thigh.

114 s.c. A431 epidermoid carcinoma and injected i.m. with 100 microg of IFN-omega pDNA, twice per week f

115 When RiVax was injected i.m. into mice it protected them against a ricin challen

116 Whether RDAd vectors were injected i.m. or i.v. or through an i.p. route, the extent of lys

117 melanoma, or glioma 261 tumors were injected i.m. with mIFN-alpha pDNA.

118 by needle i.m. or needleless jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers.

119 ce than RH30-S cells and (b) mice inoculated i.m. with the RH30-L cells had more rhabdomyosarcoma cel

120 .c.), intradermal (i.d.), and intramuscular (i.m.) administration of a trivalent influenza vaccine (T

121 , intraperitoneal (i.p.), and intramuscular (i.m.) routes of injection of alphaS fibrils and other pr

122 urrent intradermal (i.d.) and intramuscular (i.m.) vaccinations as a DNA-priming strategy for their a

123 ompared to those generated by intramuscular (i.m.) gB DNA and i.n. live HSV administration.

124 gnitude to those generated by intramuscular (i.m.) immunization.

125 Systemic immunization by intramuscular (i.m.) injection can drive mucosal immune responses, but

126 mid DNA vaccines delivered by intramuscular (i.m.) injection or delivered intradermally by Gene Gun i

127 Once daily intramuscular (i.m.) injection for 3 d would be simpler and more approp

128 ion strategies were employed: intramuscular (i.m.), intranasal (i.n.) at a low dose and low volume, a

129 mmunocompetent mice following intramuscular (i.m.) injection with identical RDAd encoding self (murin

130 Following intramuscular (i.m.), intranasal (i.n.), or intravaginal (IVAG) immuniz

131 ng experimental inflammation (intramuscular (i.m.) typhoid vaccination) and once after placebo (i.m.

132 but clinical trials involving intramuscular (i.m.) injection of HSV-2 gB and gD in adjuvants have not

133 o mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation.

134 investigated the capacity of intramuscular (i.m.) immunization with heterologous-host rotavirus (sim

135 The capacity of intramuscular (i.m.) inoculation of mice with homologous or heterologou

136 s after intradermal (i.d.) or intramuscular (i.m.) delivery of 0.5 to 1 mg of codon-optimized DNA enc

137 Intranasal or intramuscular (i.m.) immunization of mice and i.m. immunization of rabb

138 ntradermal (i.d.) delivery or intramuscular (i.m.) injection using conventional needles.

139 via the intranasal (i.n.) or intramuscular (i.m.) route in different prime-boost combinations.

140 l env-IL-4R antagonist prime, intramuscular (i.m.) recombinant Modified Vaccinia Ankara Virus (MVA)-g

141 d vaccinia Ankara (MVA) prime/intramuscular (i.m.) protein boost regimen induced functional IgG respo

142 tudies revealed that a single intramuscular (i.m.) injection of 10(6) infectious units (i.u.) of HSV:

143 Here we report that a single intramuscular (i.m.) injection of a nonreplicating adenovirus (Ad) vect

144 A single intramuscular (i.m.) injection of as little as 10 micrograms of this pl

145 egimens incorporated a single intramuscular (i.m.) injection of the DNA vaccines to prime the immune

146 After single intramuscular (i.m.) injections, human lipoprotein lipase (hLPL) mRNA w

147 ytokine profiling reveal that intramuscular (i.m.) administration of 1Z105 and 1V270 is less reactoge

148 c mice were vaccinated by the intramuscular (i.m.) and subcutaneous (s.c.) routes with a native prepa

149 of mice were immunized by the intramuscular (i.m.) and subcutaneous (s.c.) routes with recombinant MO

150 eas immunization via e.g. the intramuscular (i.m.) or subcutaneous (s.c.) routes often stimulate weak

151 G when delivered once via the intramuscular (i.m.) route.

152 sorbent assay following three intramuscular (i.m.) injections of pCMV-Tag and were typified by a mixe

153 ia the s.s. route compared to intramuscular (i.m.) injection as used in MVA clinical trials.

154 the sciatic nerve in mice via intramuscular (i.m.) injection, ELP-curcumin conjugates underwent a the

155 unization in conjunction with intramuscular (i.m.) vaccination provided full protection of hamsters f

156 e following hind limb muscle (intramuscular [i.m.]) injection of alphaS fibrils by comparing various

157 When administered intramuscularly (i.m.) to swine, there was no induction of disease, even

158 raginase (ASP) administered intramuscularly (i.m.) weekly for 24 weeks (regimen B); or regimen A plus

159 1.2 mg of DNA administered intramuscularly (i.m.; group B), or 7.2 mg of DNA administered i.m. (high

160 ilar to those induced by an intramuscularly (i.m.) administered MVAgp120 prime/gp120 boost to allow c

161 inoculated onto the cornea, intramuscularly (i.m.), intravaginally, and intracranially.

162 mutant SIV expressing DNA, intramuscularly (i.m.) in one study and i.m. and subcutaneously in anothe

163 bats were inoculated either intramuscularly (i.m.) or subcutaneously (s.c.) with a homologous or hete

164 orally alone (oral group), intramuscularly (i.m.) alone (i.m. group), orally followed by i.m. (oral/

165 wine, since pigs inoculated intramuscularly (i.m.) with either 10(2) or 10(4) 50% hemadsorbing doses

166 rorally (p.o.) (group 1) or intramuscularly (i.m.) (group 2) or three times i.m. (group 3) with inact

167 intranasally (i.n.) and/or intramuscularly (i.m.) and subsequently challenged with RSV/A/Tracy (i.n.

168 inant plasmids were used to intramuscularly (i.m.) immunize BALB/c mice.

169 vaccine regimens utilizing intramuscularly (i.m.) administered recombinant adenovirus (rAd)-based ve

170 h those treated with high-dose CsA (62 mg/kg i.m. on day 2), low-dose CsA (25 mg/kg), an endothelin-c

171 th an iron chelator, deferoxamine, (50mg/kg, i.m.) or vehicle and killed at day-3 to examine the effe

172 Rats were treated with DFX (100 mg/ kg, i.m.) or vehicle immediately after tMCAO.

173 acute effects of BU08028 (0.001-0.01 mg/kg, i.m.) and buprenorphine (0.003-0.056 mg/kg, i.m.), the d

174 Importantly, M100907 (0.3 mg/kg, i.m.) attenuated cocaine-induced (1.0 mg/kg, i.v.) dopam

175 (saline, i.m.) or acute PCP (0.1-0.3 mg/kg, i.m.) conditions.

176 he MOP antagonist naltrexone (1.7-5.6 mg/kg, i.m.) decreased both ethanol intake and food pellets del

177 PCP (0.3 mg/kg, i.m.) exerted regionally selective effects on the dopami

178 ined to discriminate between PCP (1.0 mg/kg, i.m.) from saline in a two-key operant procedure.

179 t with previous studies, M100907 (0.3 mg/kg, i.m.) significantly attenuated drug- and cue-induced rei

180 hypothermia caused by WIN 55212-2 (5 mg/kg, i.m.), a cannabinoid agonist, was not significantly alte

181 i.m.) and buprenorphine (0.003-0.056 mg/kg, i.m.), the drugs were administered chronically using a m

182 intakes when given acutely (0.03-1.0 mg/kg, i.m.), whereas the MOP antagonist naltrexone (1.7-5.6 mg

183 ed by pretreatment with S-(-)HA966 (3 mg/kg, i.m.).

184 phy (PET) after administration (2 x 2 mg/kg, i.m., 4 h apart) of either amphetamine (Amp), n = 3, or

185 onvulsive dose of soman (77.7 micrograms/kg, i.m.).

186 Four weeks after the last i.m.-plus-s.c. immunization, mice were challenged in the

187 The i.m.-i.m.-i.m. regimen induced only modest levels of gp120-specifi

188 Immunohistochemistry was used to measure i.m. macrophage content and phenotype, and cell culture

189 of human TIMP-4 by electroporation-mediated i.m. injection of naked TIMP-4 DNA stimulates tumorigene

190 zed to receive dexamethasone [fetuses: 6 mg, i.m. every 12 hr for four doses to mother; lambs: 0.01 m

191 CSP were evaluated by immunizing BALB/c mice i.m. or epidermally and by varying the number of immuniz

192 Vaccination of mice i.m. with HSV2-gD27 provided better inhibition of challe

193 gand (CD40L) monoclonal antibody (250 microg i.m.).

194 on after chemotherapy received three monthly i.m. injections of the DNA in three dose escalation coho

195 icient subjects at various doses by multiple i.m. injections.

196 AKR/J and BALB/c mice also received multiple i.m. pAra h2 immunizations.

197 subcutaneously (s.c.), intranasally (i.n.), i.m., or transcutaneously (t.c.).

198 VA prime/i.n. boost regimen received an i.n./i.m. combined C.1086 gp120 boost.

199 Thus, maternal i.n./i.m. combined immunization is a novel strategy to enhanc

200 a malaria DNA vaccine administered by needle i.m. or needleless jet injection [i.m. or i.m./intraderm

201 Neither p.o. nor i.m. inoculation conferred significant protection agains

202 Finally, pulmonary, but not i.m., plasmid DNA vaccination protected mice from a leth

203 nst vaccine Ags, we assessed combinations of i.m. and intravaginal routes in heterologous prime-boost

204 Comparison of i.m. vaccinations with HSV2-gD27 versus gD2t in adjuvant

205 nd draining lymph nodes of mice than that of i.m. immunization.

206 One i.m. dose of Ad/VNA-Stx prevented fatal central nervous

207 Only i.m. prime followed by intravaginal boost induced concom

208 In contrast, s.c. or i.m. immunization usually results in the formation of a

209 aining lymph nodes in vivo following s.c. or i.m. immunization.

210 mals, particularly when given by the s.c. or i.m. route.

211 A and OVA+CAF09 administered via the s.c. or i.m. routes.

212 ing the lymphatic compartments after s.c. or i.m. vaccination with AS01 administered with hepatitis B

213 eceived AVA by the s.q. (reference group) or i.m. route at 0, 2, and 4 weeks and 6 months (4-SQ or 4-

214 rally followed by i.m. (oral/i.m. group), or i.m. followed by orally (i.m./oral group).

215 e in vivo, we injected mice intradermally or i.m. with plasmid DNA encoding a MHC class I-restricted

216 In contrast, intranasal or i.m. immunization with toxoid in saline without proteoso

217 le i.m. or needleless jet injection [i.m. or i.m./intradermally (i.d.)] in 14 volunteers.

218 .n. administration of CT compared to i.n. or i.m. gB DNA or i.n. live HSV immunization.

219 Two or three immunizations via the i.n. or i.m. route induced a more potent systemic and mucosal im

220 Mice that were not protected (oral or i.m./oral) had increased levels of IgA in both sera and

221 essed by using sequential i.m. and rectal or i.m. vaccination regimens.

222 s, whereas naked DNA injected either i.v. or i.m. elicited only systemic responses.

223 mended regimen of five intravenous (i.v.) or i.m. injections over 4 d.

224 (i.m. group), orally followed by i.m. (oral/i.m. group), or i.m. followed by orally (i.m./oral group

225 after immunization through the i.m. or oral/i.m. route.

226 ral/i.m. group), or i.m. followed by orally (i.m./oral group).

227 of DNA plus phosphate-buffered saline (PBS) i.m. using a needleless Biojector device.

228 typhoid vaccination) and once after placebo (i.m. saline), with the aim of characterizing effects of

229 We found that prior i.m. immunization enhanced the magnitude of mucosal viru

230 f food allergy, C3H/HeSn (C3H) mice received i.m. injections of pAra h2 plasmid DNA encoding one of t

231 bearing mice were irradiated after receiving i.m. injection of Ad.Egr-TNF at viral titers 20-100 time

232 Surprisingly, young NOD mice receiving i.m. injections of pDNA encoding insulin B chain-IgGFc w

233 nical hyperalgesia, here induced by repeated i.m. acid injection.

234 ng the mdx murine model of DMD with repeated i.m. injections of PDGF-BB.

235 (PC) and later tested under vehicle (saline, i.m.) or acute PCP (0.1-0.3 mg/kg, i.m.) conditions.

236 protection was assessed by using sequential i.m. and rectal or i.m. vaccination regimens.

237 Single i.m. injections of viral vector restored dystrophin prod

238 Here we show that a single i.m. acid injection in mice lacking SP signaling by dele

239 g antibody titers against Env after a single i.m. immunization.

240 than 60% for at least 90 days after a single i.m. injection of 10 micrograms of pVRmEpo.

241 In this study, we show that a single i.m. injection of an adeno-associated viral (AAV) vector

242 t 4, 8, and 12 wk of age were given a single i.m. injection of rAAV-murine IL-10 (10(4), 10(6), 10(8)

243 n immunocompetent animals following a single i.m. injection of RDAd encoding a self protein.

244 A single i.m. injection of recombinant AAV (rAAV)-mutant human en

245 After a single i.m. injection of the DNA vaccine encoding an HIV gag p4

246 l immunity in the lung, and protection, than i.m. immunization.

247 We previously found that i.m. inoculation of mice with the intestinal pathogen, r

248 Immunologic analysis indicated that i.m. immunization of mice with either vaccine construct

249 We have previously shown that i.m. administration of bacterially expressed murine hist

250 These results suggest that i.m. delivery of rAAV type 1-AAT (rAAV1-AAT) induces a T

251 Our findings suggest that i.m. fibrocytes most likely originate from infiltrating

252 The i.m. injected plasmid DNA remained localized to the site

253 The i.m. injection of pNeuTM or pNeuE, and to a lesser exten

254 The i.m. route of immunization induced a strong IgG response

255 The i.m.-i.m.-i.m. regimen induced only modest levels of gp1

256 (CY) injection of C57BL/6J mice bearing the i.m. 76-9 rhabdomyosarcoma resulted in a significant pro

257 taneous administration of plasmid DNA by the i.m. and i.d. routes.

258 hepatitis B surface antigen (pCMV-s) by the i.m. route resulted in higher anti-SERA titers than thos

259 i.n. route was more immunogenic than by the i.m. route, and the same was true for the boosts.

260 r extent than protein boosting by either the i.m., i.n., or t.c. route, suggesting that this route ma

261 tor-1 (IGF-1) promotes FP engraftment in the i.m. site and reversal of diabetes in a rodent model.

262 In the i.m.-gene gun (g.g.)-g.g. regimen, the mice immunized wi

263 hioglycolate-induced peritonitis models, the i.m. treatment with xylazine or UK14304, two alpha2-adre

264 c anti-HIV-1 antibody responses, neither the i.m./i.m. nor the i.n./i.m.

265 Animals immunized by only the i.m. route had high peripheral T follicular helper (pTfh

266 Animals immunized by only the i.m. route had lower antibody-dependent cellular cytotox

267 mmature dendritic cells and suggest that the i.m. APCs may be enhancing immune responses to coinjecte

268 rved 3 months after immunization through the i.m. or oral/i.m. route.

269 ncement may depend on APC recruitment to the i.m. site of injection.

270 rrent HIV vaccines under development use the i.m. route for immunization, which is relatively poor in

271 In contrast, using the i.m.-subcutaneous (s.c.)-i.m. regimen, it was found that

272 tion of p21 was accomplished in mice via the i.m. injection of p21 sense plasmid DNA complexed with c

273 ngle dose of 10(8) PFU of rPIV5-RV-G via the i.m. route showed very robust protection (90% to 100%).

274 Thus, i.m. SP mediates an unconventional NK1 receptor signal p

275 Thus, i.m. vaccination can overcome immune compartmentalizatio

276 ramuscularly (i.m.) (group 2) or three times i.m. (group 3) with inactivated Wa strain human rotaviru

277 nducing mucosal antibody, it was inferior to i.m. DNA delivery in providing protection against lethal

278 tivation of p38 and the STATs in response to i.m. injection of IFN-beta1a or stimulation in vitro.

279 utputs were collected over 3 h subsequent to i.m. administration of KOR agonists.

280 IgG subclass bias were induced subsequent to i.m. DNA immunization.

281 gag, and nef recombinants and boosted twice i.m. with SIV gp120 proteins in alum.

282 Two i.m. immunizations with proteosome-toxoid plus alum also

283 g SIV Env, Rev, Gag, and Nef followed by two i.m. boosts with monomeric SIV gp120 or oligomeric SIV g

284 f pulmonary metastasis was achieved upon two i.m. injections of pCMV-Tag, as assessed by examination

285 Unexpectedly, i.m. immunization without adjuvant conferred the highest

286 mg each of the gp120 protein boost vaccine (i.m.).

287 axfectin i.d., 100 mug of DNA plus Vaxfectin i.m. or 100 mug of DNA plus phosphate-buffered saline (P

288 70 microg/kg estradiol cypionate or vehicle i.m. once a week.

289 s demonstrate the superiority of i.n. versus i.m. vaccination in protection against both lethal chall

290 ls of antibody similar to those produced via i.m. injection during the first 2 weeks following primar

291 We examined whether i.m. injection of either of these plasmids could induce

292 The mechanisms by which i.m. inoculation induces virus-specific humoral immune r

293 A cancer treatment is described in which i.m. injection of plasmid DNA (pDNA) encoding murine int

294 otection from aerosol spore challenge, while i.m. injection of the same dose provided slightly lower

295 enge with NFSA(MART1) could be achieved with i.m. injections of a MART-1 expression plasmid or with s

296 profibrotic growth factors as compared with i.m. fibroblasts.

297 nses in mice at a reduced dose compared with i.m. immunization.

298 Priming systemic immune responses with i.m. immunization with ALVAC-SIV vaccines, followed by i

299 mice in the control groups, with or without i.m. injection of a control vector AAV-GFP, died because

300 d alefacept (two 12-week courses of 15 mg/wk i.m., separated by a 12-week pause) with placebo in pati